AceLink Therapeutics Completes 6-Month Primary Phase of AL01211 Clinical Study in Fabry Disease Patients
AceLink Therapeutics, a clinical-stage biopharmaceutical company developing best-in-class substrate reduction therapies for lysosomal storage disorders, today announced the successful completion of the 6-month primary treatment phase of its ongoing Phase 2 study of AL01211 in treatment-naive male patients with classic Fabry disease.
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025
AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim data from its ongoing Phase 2 clinical study of AL01211 in treatment-naïve, classic male Fabry disease patients. These findings were highlighted in a late-breaking oral platform presentation at the 2025 WORLD Symposium in San Diego, California.
